Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 40, 2008, Pages 15541-15546

  Yano, Akihiro ^a   Tsutsumi, Shinji ^a   Soga, Shiro ^a,c   Lee, Min Jung ^a   Trepel, Jane ^a   Osada, Hiroyuki ^b   Neckers, Len ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Japan Science and Technology Agency   (Japan)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Cancer; Geldanamycin; Heat shock protein 90; Osteoclastogenesis

Indexed keywords

ALENDRONIC ACID; BETA3 INTEGRIN; DASATINIB; HEAT SHOCK PROTEIN 90; PROTEIN KINASE B; TANESPIMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE; CANCER GROWTH; CARCINOMA CELL; CELL MATURATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE SRC; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; BENZOQUINONES; BONE NEOPLASMS; CARCINOMA; HSP90 HEAT-SHOCK PROTEINS; IMMUNOPRECIPITATION; INTEGRIN BETA3; LACTAMS, MACROCYCLIC; MALE; MICE; MICE, INBRED C57BL; ONCOGENE PROTEIN V-AKT; OSTEOCLASTS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 55749096409     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0805354105     Document Type: Article

References (47)

1. Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55-S61.
2. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772.
3. Workman P, Burrows F, Neckers L, Rosen N (2007) Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 1113:202-216.
4. Solit DB, et al. (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-993.
5. Bisht KS, et al. (2003) Geldanamycin and 17-allylamino-17- demethoxygeldanamycin potentiate the in vitroandin vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63:8984-8995.
6. Mitsiades CS, et al. (2006) Antimyeloma activity of heat shock protein-90 inhibition. Blood 107:1092-1100.
7. Modi S, et al. (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A phase I dose-escalation study. J Clin Oncol 25:5410-5417.
8. Koga F, et al. (2006) Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci USA 103:11318-11322.
9. Donze O, Abbas-Terki T, Picard D (2001) The Hsp90 chaperone complex is both a facilitator and a repressor of the dsRNA-dependent kinase PKR. EMBO J 20:3771-3780.
10. Yun BG, Matts RL (2005) Hsp90 functions to balance the phosphorylation state of Akt during C2C12 myoblast differentiation. Cell Signal 17:1477-1485.
11. Citri A, et al. (2004) Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep 5:1165-1170.
12. Lattouf JB, Srinivasan R, Pinto PA, Linehan WM, Neckers L (2006) Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nat Clin Practice 3:590-601.
13. Solit DB, Rosen N (2006) Hsp90: A novel target for cancer therapy. Curr Top Med Chem 6:1205-1214.
14. Saporita AJ, Ai J, Wang Z (2007) The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 67:509-520.
15. Williams CR, Tabios R, Linehan WM, Neckers L (2007) Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol 178:1528-1532.
16. Eccles SA, et al. (2008) NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68:2850-2860.
17. Niu G, Cai W, Chen K, Chen X (2008) Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor. Mol Imaging Biol 10:99-106.
18. Price JT, et al. (2005) The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 65:4929-4938.
19. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342.
20. Miyazaki T, et al. (2004) Src kinase activity is essential for osteoclast function. J Biol Chem 279:17660-17666.
21. Yoshida H, et al. (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442-444.
22. Dai XM, et al. (2002) Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99:111-120.
23. Boyce BF, et al. (2003) Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases Kidney Int, S2-5.
24. Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s-6230s.
25. Woo JT, et al. (2006) Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci USA 103:4729-4734.
26. Hotokezaka H, et al. (2002) U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277:47366-47372.
27. Sugatani T, Hruska KA (2005) Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 280:3583-3589.
28. Yang M, et al. (2006) Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: A key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro. Blood 107:2262-2270.
29. Insogna KL, et al. (1997) Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts. J Clin Invest 100:2476-2485.
30. Sakai H, et al. (2006) Activated c-Fms recruits Vav and Rac during CSF-1-induced cytoskeletal remodeling and spreading in osteoclasts. Bone 39:1290-1301.
31. Boissy P, et al. (1998) Aggregation of mononucleated precursors triggers cell surface expression of alphavbeta3 integrin, essential to formation of osteoclast-like multinucleated cells. J Cell Sci 111:2563-2574.
32. Datta A, Huber F, Boettiger D (2002) Phosphorylation of beta3 integrin controls ligand binding strength. J Biol Chem 277:3943-3949.
33. Ross FP, Teitelbaum SL (2005) alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 208:88-105.
34. Jemal A, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
35. Zhang J, et al. (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235-1244.
36. Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91:718-729.
37. Soriano P, Montgomery C, Geske R, Bradley A (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702.
38. Faccio R, et al. (2005) Vav3 regulates osteoclast function and bone mass. Nat Med 11:284-290.
39. von Bubnoff N, Peschel C, Duyster J (2003) Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): A targeted oncoprotein strikes back. Leukemia 17:829-838.
40. Kobayashi S, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792.
41. Engelman JA, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043.
42. Morgillo F, et al. (2007) Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13:2795-2803.
43. Xu W, Neckers L (2007) Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 13:1625-1629.
44. Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J (2006) Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res 66:5387-5393.
45. Weisberg E, et al. (2008) Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Molecular Cancer Ther 7:1121-1129.
46. Johnson FM, Saigal B, Talpaz M, Donato NJ (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11:6924-6932.
47. Xu W, et al. (2001) Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90 J Biol Chem 276:3702-3708.